Exosomal protein interactors as emerging therapeutic targets in urothelial bladder cancer

الملخص EN

Background : Exosomes are rich sources of biological material (proteins and nucleic acids) secreted by both tumor and normal cells, and found in urine of urinary bladder cancer patients.

Objective : The objective of the study was to identify interacting exosomal proteins in bladder cancer for future use in targeted therapy.

Methods : The Exocarta database (www.exocarta.org) was mined for urinary bladder cancer specific exosomal proteins.

The urinary bladder cancer specific exosomal proteins (n = 248) were analyzed to identify enriched pathways by Onto-tool Pathway Express (http : / / vortex.cs.wayne.edu / ontoexpress).

Results : Enriched pathways included cellular architecture, motility, cell to cell adhesion, tumorigenesis and metastasis.

Proteins in the 9 top-ranked pathways included CTNNA1 (alpha-catenin), CTNNB1 (beta-catenin), VSAP, ITGA4, PAK1, DDR1, CDC42, RHOA, NRAS, RHO, PIK3AR1, MLC1, MMRN1, and CTTNBP2 and network analysis revealed 10 important hub proteins and identified inferred interactor NF2.

Conclusions: The importance of identifying interactors is that that they can be used as targets for therapy, for example, using Bevacizumab (avastin-an angiogenesis inhibitor) against NF2 to inhibit protein-protein interactions will inhibit tumor growth and progression by hindering the exosome biogenesis.

ª 2015 Production and hosting by Elsevier B.

V.

on behalf of National Cancer Institute, Cairo University.

This is an open access article under the CC BY-NC-ND license